Search Results Heading

MBRLSearchResults

mbrl.module.common.modules.added.book.to.shelf
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Are you sure you want to remove the book from the shelf?
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
    Done
    Filters
    Reset
  • Discipline
      Discipline
      Clear All
      Discipline
  • Is Peer Reviewed
      Is Peer Reviewed
      Clear All
      Is Peer Reviewed
  • Series Title
      Series Title
      Clear All
      Series Title
  • Reading Level
      Reading Level
      Clear All
      Reading Level
  • Year
      Year
      Clear All
      From:
      -
      To:
  • More Filters
      More Filters
      Clear All
      More Filters
      Content Type
    • Item Type
    • Is Full-Text Available
    • Subject
    • Country Of Publication
    • Publisher
    • Source
    • Target Audience
    • Donor
    • Language
    • Place of Publication
    • Contributors
    • Location
378 result(s) for "Naik, Anita"
Sort by:
Multi‐Gene Pharmacogenomic Testing in a Community‐Based Setting Is Feasible and Reduces Total Healthcare Costs
Pharmacogenomic (PGx) testing using multi‐gene panels (mgPGx) is documented to improve clinical outcomes; however, real‐world data on its economic impact remain limited. This study aimed to evaluate the utility and economic value of mgPGx testing among Medicare patients within a community‐based health system. We identified Medicare Advantage patients within the primary care setting of a community‐based health system hospital who were taking ≥ 1 PGx‐guided medication using a stratification algorithm. In total, 1042 patients participated in mgPGx testing. We evaluated the prevalence of PGx medications, polypharmacy involving PGx medications, and actionable results (i.e., a phenotype with PGx guidance and a relevant PGx medication). A Total Cost of Care (TCOC) analysis was performed for a subset of patients (n = 548) who underwent PGx testing and were matched to a control group that did not undergo PGx testing using propensity score matching. Total medical expenses over 12 months, both before and after testing, were compared. Forty‐four percent (n = 454/1042) of patients were ≥ 3 PGx‐guided medications. Over one‐third of patients who were on ≥ 3 PGx medications had ≥ 2 actionable results (35.5%, n = 161/454). The TCOC analysis demonstrated a trend toward a net cost savings of$1827 per member per year (PMPY), with $ 1582 in medical savings and $245 in pharmacy savings. Polypharmacy with PGx medications is prevalent, and mgPGx led to cost savings. Further research with a larger sample size is needed to replicate the results and assess the long‐term impact on healthcare utilization and costs.
The Detection and Partial Localisation of Heteroplasmic Mutations in the Mitochondrial Genome of Patients with Diabetic Retinopathy
Diabetic retinopathy (DR) is a common complication of diabetes and a major cause of acquired blindness in adults. Mitochondria are cellular organelles involved in energy production which contain mitochondrial DNA (mtDNA). We previously showed that levels of circulating mtDNA were dysregulated in DR patients, and there was some evidence of mtDNA damage. In the current project, our aim was to confirm the presence of, and determine the location and prevalence of, mtDNA mutation in DR. DNA isolated from peripheral blood from diabetes patients (n = 59) with and without DR was used to amplify specific mtDNA regions which were digested with surveyor nuclease S1 to determine the presence and location of heteroplasmic mtDNA mutations were present. An initial screen of the entire mtDNA genome of 6 DR patients detected a higher prevalence of mutations in amplicon P, covering nucleotides 14,443 to 1066 and spanning the control region. Further analysis of 42 subjects showed the presence of putative mutations in amplicon P in 36% (14/39) of DR subjects and in 10% (2/20) non-DR subjects. The prevalence of mutations in DR was not related to the severity of the disease. The detection of a high-prevalence of putative mtDNA mutations within a specific region of the mitochondrial genome supports the view that mtDNA damage contributes to DR. The exact location and functional impact of these mutations remains to be determined.
Good day sunshine: Top tips to stay sun-smart this summer
The SPF is a measure of how well a sunscreen will shield your skin from UVB rays, which penetrate the top layer of skin and are the chief cause of sunburns, and the star rating shows the level of protection against damaging UVA rays, which penetrate deeper into the skin.
You could hope they secretly know you like them... or try this
Sure, it's great to have a cute story to tell or rock some cool concert tee for them to notice, but in the real world you aren't always going to have timely tales or fun props-you'll only have yourself. Science shows that people find it hard to ignore good-vibes energy, so grab their attention by smiling and having fun with your crew. Might be cheesy, but remembering bits of info and working them into conversation isn't just flattering-it also shows you're interested because you've paid attention.
Your LIFE: 7 questions you MUST ask your mother ; REAL STORIES
If you're putting off motherhood and want an idea of when you might hit the menopause, ask Mum. Dr Judith Reichman says: \"If she stopped earlier in life, the chances are you will, too.\" \"Diabetes, high blood pressure and high cholesterol have genetic links,\" warns TV's Dr David Bull. So find out what Mum's GP said - it could hit you later.